Literature DB >> 16900573

A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.

Todd A Schwartz1, Jonathan S Denne.   

Abstract

Many non-inferiority trials of a test treatment versus an active control may also, if ethical, incorporate a placebo arm. Inclusion of a placebo arm enables a direct assessment of assay sensitivity. It also allows construction of a non-inferiority test that avoids the problematic specification of an absolute non-inferiority margin, and instead evaluates whether the test treatment preserves a pre-specified proportion of the effect of the active control over placebo. We describe a two-stage procedure for sample size recalculation in such a setting that maintains the desired power more closely than a fixed sample approach when the magnitude of the effect of the active control differs from that anticipated. We derive an allocation rule for randomization under which the procedure preserves the type I error rate, and show that this coincides with that previously presented for optimal allocation of the sample size among the three treatment arms. Copyright 2006 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2006        PMID: 16900573     DOI: 10.1002/sim.2651

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  1 in total

1.  A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease.

Authors:  Hong Liu-Seifert; Scott W Andersen; Ilya Lipkovich; Karen C Holdridge; Eric Siemers
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.